ZINACEF INJECTION - PWS IV 7.5GM/VIAL 7.5 G
CEFUROXIME SODIUM : 7.5 G · DIN 02213559 · GLAXOSMITHKLINE INC
Health Canada status: CANCELLED POST MARKET
What is ZINACEF INJECTION - PWS IV 7.5GM/VIAL?
ZINACEF INJECTION - PWS IV 7.5GM/VIAL 7.5 G contains CEFUROXIME SODIUM : 7.5 G. It is listed in the Health Canada Drug Product Database under DIN 02213559, held by GLAXOSMITHKLINE INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 09-Jul-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZINACEF INJECTION - PWS IV 7.5GM/VIAL used for?
Treatment of lower respiratory tract, urinary tract, soft tissue, bone and joint infections, meningitis, and gonorrhoea caused by susceptible organisms. Also used for surgical prophylaxis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is ZINACEF INJECTION - PWS IV 7.5GM/VIAL called?
The same molecule, CEFUROXIME, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Zinnat | Latin | Australia, Morocco |
| Pharmacor Cefuroxime | Latin | Australia |
| Betaroxime | Latin | South Africa |
| CEROXIM | Latin | Morocco |
| Ceroxim Forte Suspension | Latin | South Africa |
| Ceroxim Suspension | Latin | South Africa |
| Furocsem | Latin | South Africa |
| Zinnat (UK) | Latin | Australia |
| Sandoz Cefuroxime | Latin | South Africa |
| ZINACEF | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02213559 |
|---|---|
| Brand name | ZINACEF INJECTION - PWS IV 7.5GM/VIAL |
| Generic / active ingredient | CEFUROXIME SODIUM : 7.5 G |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 7.5 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DC02 CEFUROXIME |
| AHFS class | 08:12.06.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-Jul-2007 |
| Original market date | 2002-01-17 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02213559 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2213559 |
| Brand name | ZINACEF INJECTION - PWS IV 7.5GM/VIAL |
| Active ingredient / INN | CEFUROXIME SODIUM : 7.5 G |
| ATC code | J01DC02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:12.06.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | GLAXOSMITHKLINE INC |
How is it administered?
Adults: 750 mg to 1.5 g every 8 hours IV or IM. Meningitis: 3 g IV every 8 hours. Infants/Children: 30-100 mg/kg/day in 3-4 divided doses. Neonates: 30-100 mg/kg/day in 2-3 divided doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Dry state: Store below 25°C and protect from light. Reconstituted: 6 hours at <25°C or 48 hours refrigerated.
How is it supplied?
750 mg vials (packs of 10), 1.5 g vials (packs of 10), and 7.5 g Pharmacy Bulk Vials (packs of 6).
Which pack is which?
| Strength on the label | 7.5 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Packaging as described in the monograph | 750 mg vials (packs of 10), 1.5 g vials (packs of 10), and 7.5 g Pharmacy Bulk Vials (packs of 6). |
| Storage | Dry state: Store below 25°C and protect from light. Reconstituted: 6 hours at <25°C or 48 hours refrigerated. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Contraindications
Contraindicated in patients with Type 1 hypersensitivity to cefuroxime or the cephalosporin group of antibiotics.
Warnings and precautions
Hypersensitivity reactions (cross-reactivity with penicillins possible). Pseudomembranous colitis risk. Nephrotoxicity risk when used with potent diuretics or aminoglycosides.
What can be used instead?
Other Canadian products sharing ATC code J01DC02 CEFUROXIME. 9 of 44 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CEFUROXIME | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02244393 |
| APO-CEFUROXIME | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02244394 |
| AURO-CEFUROXIME | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02344823 |
| AURO-CEFUROXIME | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02344831 |
| CEFTIN | 125 MG / 5 ML | GRANULES FOR SUSPENSION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02212307 |
| CEFUROXIME FOR INJECTION, USP | 1.5 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02241639 |
| CEFUROXIME FOR INJECTION, USP | 750 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02241638 |
| JAMP CEFUROXIME | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02547198 |
| JAMP CEFUROXIME | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02547201 |
| CEFTIN - PWR 250MG/SACHET | 250 MG | POWDER | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02212293 |
Who else supplies CEFUROXIME worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFUROXIME appears in 39 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CEFUROXIME cost around the world?
CEFUROXIME is listed on 5 national price registers Nexara tracks, across 98 pack listings published on 5 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 42 | 47 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 24 | 24 | 03 Sep 2026 |
| Morocco | PPV (public price) | 5 | 14 | 05 Sep 2026 |
| Australia | ex-manufacturer | 3 | 8 | 08 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.